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• Approximately 2-7% of people with stage III or IV NSCLC have chromosomal alterations described as anaplastic lymphoma kinase (ALK) fusion genes 2 • Crizotinib, the first approved ALK inhibitor (ALKi), significantly increased progressionfree survival (PFS) compared to chemotherapy among ALK-positive (ALK+) advanced or metastatic NSCLC patients with or without prior platinum-based chemotherapy 3, 4 • However, about one-third of cancers that relapsed or were refractory to crizotinib had evidence of resistance mutations in the ALK tyrosine kinase domain 5 • Ceritinib was approved in the European countries for the treatment of patients with ALK+ advanced NSCLC previously treated with crizotinib 6 The Phase I trial (ASCEND-1, NCT01283516) showed durable anti-tumor activity in both crizotinib naïve and crizotinib experienced ALK+ NSCLC patients 7 
-
The Phase II trial (ASCEND-2, NCT01685060) among patients who progressed on chemotherapy and crizotinib reported a median PFS of 5.7 months by investigator review and a median overall survival (OS) of 14.9 months 8 -Another Phase II trial (ASCEND-3, NCT01685138) among patients who progressed on chemotherapy but were ALKi-naïve reported a median PFS of 11.1 months by investigator review 9 
OBJECTIVE
• To assess the cost-effectiveness of ceritinib versus alternatives in the treatment of ALK+ advanced or metastatic NSCLC in the UK
METHODS

Model Overview
• A partitioned survival model with three mutually exclusive health states: stable disease, progressive disease, and death was developed (Figure 1) Post-ALKi population
• PFS (investigator assessment) and OS for ceritinib in the post-ALKi population were estimated using data from the ASCEND-1 (data cut April 14, 2014) 7 and ASCEND-2 (data cut August 13, 2014) 8 trials -Different parametric models (i.e., exponential, Weibull, log-logistic, log-normal, and Gompertz) were applied to extrapolate outcomes beyond the trial period -Weibull distribution was selected for both PFS and OS based on the best statistical fit • For comparators, published Kaplan-Meier (KM) curves for PFS and OS were extracted using digitization software to generate approximate patient-level time-to-event data using the approach described by Guyot P, et al.
12
Parametric models using the same function as ceritinib were applied to extrapolate outcomes beyond the trial period Studies selected for efficacy inputs for Post-CT and Post-ALKi populations are summarized in Table 1 . 
Sensitivity Analysis
• For each population, one-way sensitivity analyses (SAs) were used to examine the impact of change in one key model input and/or assumption, while holding others at the basecase value. The inputs included efficacy outcomes extrapolated by different parametric models, utilities, drug costs, medical costs associated with health states, AE disutilities and costs, time horizons, and discount rate • For each population, a multivariate probabilistic sensitivity analysis (PSA) was also conducted using a Monte Carlo simulation of 1,000 iterations -The PSA included model inputs such as: efficacy outcomes extrapolated by different parametric models, utilities, relative dose intensities, and medical costs
RESULTS
Post-CT population Base case over a 10-year horizon ( One-way SAs Ceritinib PFS function -log-normal Ceritinib OS function -Gompertz Ceritinib PFS function -log-logistic Drug dose intensity assumed to be 100% Ceritinib PFS function -exponential Discount rate: effectiveness (0, 6%) Discount rate: cost (0, 6%) Ceritinib PFS function -Gompertz Utility of progressive disease state (base case ± 10%)
Ceritinib OS function -log-logistic Ceritinib OS function -log-normal Consider oral chemotherapy drug administration cost Post-progression medical cost (base case ± 25%) Utility of stable disease state with no toxicity (base case ± 10%)
Pre-progression medical cost (base case ± 25%) Assume no response rate adjustment for stable disease state utility
Terminal care cost (one time) (base case ± 25%) Cost of AEs (no AE, 2x base case value) Ceritinib PFS function -Weibull
Incremental cost per QALY gained
Low SA value High SA value Dominant PSA (Figure 3) • At a willingness-to-pay (WTP) threshold of £50,000 per QALY gained, the Monte Carlo simulation varying all variables simultaneously showed that ceritinib was cost-effective in 83.6% of cases compared with crizotinib, whereas the figure was 56.3% compared with docetaxel, and 77.6% compared with pemetrexed, respectively Post-ALKi Base case over a 10-year horizon (Table 5) • Ceritinib was associated with 0.94 QALYs, 1.77 LYs, and total direct costs of £44,043
• Ceritinib was associated with additional 0.76, 0.58, and 0.54 QALYs, and 1.47, 1.09, and 1.09 LYs compared with BSC, docetaxel, and pemetrexed, respectively. The incremental costs for ceritinib was £38,878, £34,890, and £23,447 compared with BSC, docetaxel, and pemetrexed, respectively
The incremental costs per QALY gained for ceritinib vs BSC, docetaxel, and pemetrexed were £50,997, £60,556, and £43,221, respectively. The incremental costs per LY gained was £26,403, £32,086, and £21,562, respectively One-way SAs 
PSA (Figure 5)
• At the same WTP threshold of £50,000 per QALY gained, ceritinib was cost-effective in 35.8% of cases compared with BSC, whereas the figure was 4.2% compared with docetaxel and 68.8% compared with pemetrexed, respectively 
Discussion
• The results were robust to different assumptions and model inputs
• Using the WTP threshold of £50,000 for drugs designed to extend life at the end of life, the current study results suggested that ceritinib could be considered cost-effective compared to alternatives for previously treated patients with ALK+ NSCLC
Limitations
• No head-to-head evidence was available for ceritinib compared with other comparator arms. Indirect comparisons were used whenever possible
• At the point of current analysis, the comparative results might be limited by immature survival data for relatively small sample sizes in some ceritinib trials
• PFS and OS outcomes based on the trials were extrapolated to the rest of the model period
CONCLUSIONS
• Based on the WTP threshold for end -of-life cancer drugs, ceritinib may be considered as a cost-effective option compared with alternatives for previous treated patients with ALK+ NSCLC
